共 50 条
- [31] Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled DesignCNS DRUGS, 2020, 34 (08) : 867 - 877Wu, MinLi, CuiyunZhang, HongSun, JixuanZhu, XiaoxueLi, XiaojiaoGao, XuedongWang, WeiDing, Yanhua
- [32] Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled DesignCNS Drugs, 2020, 34 : 867 - 877Min WuCuiyun LiHong ZhangJixuan SunXiaoxue ZhuXiaojiao LiXuedong GaoWei WangYanhua Ding
- [33] A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody ( Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa InfectionCLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1624 - E1631Legrand, FannyHerrick, JesicaMakiya, MichelleRamanathan, RoshanThompson, ReaganRampertaap, ShakuntalaStoddard, JenniferWare, JeanAnneFay, Michael P.Holland-Thomas, NicoleNutman, Thomas B.Klion, Amy D.
- [34] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PILOT STUDY OF SINGLE-DOSE HUMANIZED ANTI-IL5 ANTIBODY (RESLIZUMAB) FOR THE REDUCTION OF EOSINOPHILIA FOLLOWING DIETHYLCARBAMAZINE TREATMENT OF LOA LOA INFECTIONAMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 187 - 187Legrand, FannyHerrick, JesicaMakiya, MichelleRampertaap, ShakuntalaStoddard, JenniferWare, JeanAnneFay, Michael P.Holland-Thomas, NicoleNutman, Thomas B.Klion, Amy
- [35] Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled studyEUROPEAN HEART JOURNAL, 2021, 42 (02) : 178 - 188Taubel, JorgHauke, WilfriedRump, SteffenViereck, JanikaBatkai, SandorPoetzsch, JennyRode, LauraWeigt, HenningGenschel, CelinaLorch, UlrikeTheek, CarmenLevin, Arthur A.Bauersachs, JohannSolomon, Scott D.Thum, Thomas
- [36] A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Intravenous Dose Study of VGL101, a Novel TREM2 Agonist, in Healthy Volunteers (HVs)ANNALS OF NEUROLOGY, 2023, 94 : S68 - S68Meier, AndreasPapapetropoulos, SpyrosMarsh, AndrewNeelon, KellyThackaberry, EvanStiles, DavidO'Mara, RyanRajagovindan, Raj
- [37] Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)Prasenohadi, PrasenohadiBurhan, ErlinaDhunny, SriSuharno, WahyuningsihWabnitz, PaulKim, Yoon-WonPetrosillo, Nicola
- [38] RESULTS FROM A MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPYANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 61 - 61Hsu, B.Sheng, S.Weinblatt, M. E.Smolen, J. S.
- [39] Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Human Monoclonal Antibody TQC2731 Targeting Thymic Stromal Lymphopoietin in Healthy Adults: A First-in-human, Randomized, Placebo-controlled, Double-blind, Phase 1 StudyJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB20 - AB20Tian, XinZhang, Xiaojian
- [40] INFLAMMATORY AND ANEMIA-RELATED MARKERS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SILTUXIMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) IN MULTICENTRIC CASTLEMAN'S DISEASE PATIENTSHAEMATOLOGICA, 2014, 99 : 465 - 465Casper, C.Chaturvedi, S.Munshi, N.Wong, R.Qi, M.Schaffer, M.Bandekar, R.Huang, Y.Hall, B.Vermeulen, J.Reddy, M.Van Rhee, F.